

used to test whether the group effect (weight gainers vs. weight-stable) was independent of factors such as percent body fat.

Acknowledgments

We are indebted to Roger Lallone for establishing the ELISA and immunopurifying the anti-leptin antibody. We are also indebted to the staff of the Clinical Research Unit, especially Rod Norman and Rob Hanson for their help and suggestions for the statistical analysis. Finally, we thank the residents and leaders of the Gila River Indian Community for their long-standing support for these studies.

RECEIVED 3 OCTOBER; ACCEPTED 5 DECEMBER 1996

1. Zhang, Y. *et al.* Positional cloning of the mouse obese gene and its human homologue. *Nature* **372**, 425–432 (1994).
2. Mhalaas, J.L. *et al.* Weight-reducing effects of the plasma protein encoded by the obese gene. *Science* **269**, 543–546 (1995).
3. Pellemounter, M.A. *et al.* Effects of the obese gene product on body weight regulation in *ob/ob* mice. *Science* **269**, 540–543 (1995).
4. Campfield, L.A., Smith, F.J., Guisez, Y., Devos, R. & Burn, P. Recombinant mouse *ob* protein: Evidence for a peripheral signal linking adiposity and central neural networks. *Science* **269**, 546–549 (1995).
5. Schwartz, M.W. *et al.* Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in *ob/ob* mice. *Diabetes* **45**, 531–535 (1996).
6. Maffei, M. *et al.* Leptin levels in human and rodent: Measurement of plasma leptin and *ob* RNA in obese and weight-reduced subjects. *Nature Med.* **1**, 1155–1161 (1995).
7. Considine, R.V. *et al.* Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *N. Engl. J. Med.* **334**, 292–295 (1996).
8. Coleman, D.L. Obese and diabetes: Two mutant genes causing diabetes-obesity syndromes in mice. *Diabetologia* **14**, 141–148 (1978).
9. Tartaglia, L.A. *et al.* Identification and expression cloning of a leptin receptor, *OB-R*. *Cell* **85**, 1265–1271 (1995).
10. Lee, G.-H. *et al.* Abnormal splicing of the leptin receptor in diabetic mice. *Nature* **379**, 632–635 (1996).

11. Schwartz, M.W., Boyko, E.J., Kahn, S.E., Ravussin, E. & Bogardus, C. Reduced insulin secretion: An independent predictor of body weight gain. *J. Clin. Endocrinol. Metab.* **80**, 1571–1576 (1995).
12. Swinburn, B.A. *et al.* Insulin resistance associated with lower rates of weight gain in Pima Indians. *J. Clin. Invest.* **88**, 168–173 (1991).
13. Ravussin, E. *et al.* Reduced rate of energy expenditure as a risk factor for body-weight gain. *N. Engl. J. Med.* **318**, 467–472 (1988).
14. Maffei, M. *et al.* The human *obese* gene: Isolation, characterization, identification of a DNA polymorphism and mutation screening in obese/diabetic subjects. *Diabetes* **45**, 679–682 (1996).
15. Considine, R.V. *et al.* Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity. *J. Clin. Invest.* **95**, 2986–2988 (1995).
16. Norman, R.A. *et al.* Absence of linkage of obesity and energy metabolism to markers flanking homologues of rodent obesity genes in Pima Indians. *Diabetes* **45**, 1229–1232 (1996).
17. Stirling, B. *et al.* Identification of microsatellite markers near the human *OB* gene and linkage studies in NIDDM-affected sib pairs. *Diabetes* **44**, 999–1001 (1995).
18. Reed, D.R. *et al.* Extreme obesity may be linked to markers flanking the human *OB* gene. *Diabetes* **45**, 691–694 (1996).
19. Clément, K. *et al.* Indication of linkage of the human *OB* gene region with extreme obesity. *Diabetes* **45**, 687–690 (1996).
20. Saladin, R. *et al.* Transient increase in *obese* gene expression after food intake or insulin administration. *Nature* **377**, 527–529 (1995).
21. Kolaczynski, J.W. *et al.* Acute and chronic effect of insulin on leptin production in humans: Studies in vivo and in vitro. *Diabetes* **45**, 699–701 (1996).
22. Stephens, T.W. *et al.* The role of neuropeptide Y in the antiobesity action of the *obese* gene product. *Nature* **377**, 530–532 (1995).
23. Schwartz, M.W., Peskind, E., Raskind, M., Boyko, E.J. & Porte, D., Jr. Cerebrospinal fluid leptin levels: Relationship to plasma levels and to adiposity in humans. *Nature Med.* **2**, 589–592 (1996).
24. Collins, S. *et al.* Leptin stimulates sympathetic outflow to brown adipose tissue. *Nature* **380**, 677 (1996).
25. Spraul, M. *et al.* Reduced sympathetic nervous activity: A potential mechanism predisposing to body weight gain. *J. Clin. Invest.* **92**, 1730–1735 (1993).
26. Neel, J.V. Diabetes mellitus: A "thrifty" genotype rendered detrimental by "progress." *Am. J. Hum. Genet.* **14**, 353–362 (1962).
27. Ahima, R.S. *et al.* Role of leptin in the neuroendocrine response to fasting. *Nature* **382**, 250–252 (1996).
28. Lillioja, S. *et al.* Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. *N. Engl. J. Med.* **329**, 1988–1992 (1993).

CORRIGENDA

Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial

A.A. VANDENBARK, Y.K. CHOU, R. WHITHAM, R. MASS, A. BUENAFE, D. LIEFELD, D. KAVANAGH, S. COOPER, G. A. HASHIM, H. OFFNER & D.N. BOURDETTE

Nature Medicine **2**, 1109–1115 (1996)

On page 1110, the protocol for patients should read: Each patient received 100 µg peptide or diluent in 0.1 weekly for 4 weeks, and then every four weeks for an additional 10 months, for a total of 15 injections. The changes are underlined. On page 1112, in the table of statistical analyses, part *d*, MBP response vs. clinical outcome, the first line should read ↓ or no change in MBP.

Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys

MARIA J. CROWE, JACQUELINE C. BRESNAHAN, SHERI L. SHUMAN, JEFFERY N. MASTERS & MICHAEL S. BEATTIE

Nature Medicine **3**, 73–76 (1997)

On page 75, figure 4 was printed incorrectly. The correct figure is displayed below.

